Journal Article

Accelerating the Development and Validation of New Value-Based Diagnostics by Leveraging Biobanks

Cronin, Maureen, Zatloukal, Kurt, Horgan, Denis, Schneider, Daniel, Moch, Holger, Negrouk, Anastassia, Balling, Rudi, Riegman, Peter H.J., Penault-Llorca, Frederiques

2016

Overview

The challenges faced in developing value-based diagnostics has resulted in few of these tests reaching the clinic, leaving many treatment modalities without matching diagnostics to select patients for particular therapies. Many patients receive therapies from which they are unlikely to benefit, resulting in worse outcomes and wasted health care resources. The paucity of value-based diagnostics is a result of the scientific challenges in developing predictive markers, specifically: (1) complex biology, (2) a limited research infrastructure supporting diagnostic development, and (3) the lack of incentives for diagnostic developers to invest the necessary resources. Better access to biospecimens can address some of these challenges. Methodologies developed to evaluate biomarkers from biospecimens archived from patients enrolled in randomized clinical trials offer the greatest opportunity to develop and validate high-value molecular diagnostics. An alternative opportunity is to access high-quality biospecimens collected from large public and private longitudinal observational cohorts such as the UK Biobank, the US Million Veteran Program, the UK 100,000 Genomes Project, or the French E3N cohort. Value-based diagnostics can be developed to work in a range of samples including blood, serum, plasma, urine, and tumour tissue, and better access to these high-quality biospecimens with clinical data can facilitate biomarker research.

• Publisher: S. Karger AG
• Subject: Biological Specimen Banks / Further Section / Humans / Informed Consent / Pathology, Molecular - standards / Precision Medicine / Value-Based Purchasing
• ISBN: 9783318059021, 3318059021